Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

• Anton Hagenbeek,
• Hans Mooij,
• Josée Zijlstra,
• Pieternella Lugtenburg,
• Gustaaf van Imhoff,
• Marcel Nijland,
• Sanne Tonino,
• Martin Hutchings,
• Marjolein Spiering,
• Roberto Liu,
• Harm van Tinteren,
• Marie José Kersten

Affiliations

Anton Hagenbeek

Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands

Hans Mooij

Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands

Josée Zijlstra

Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands

Pieternella Lugtenburg

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

Gustaaf van Imhoff

Department of Hematology, University Medical Center Groningen, the Netherlands

Marcel Nijland

Department of Hematology, University Medical Center Groningen, the Netherlands

Sanne Tonino

Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands;Lymphoma and Myeloma Center Amsterdam (LYMMCARE), the Netherlands

Martin Hutchings

Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark

Marjolein Spiering

Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands

Roberto Liu

Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands

Harm van Tinteren

Biometric Department, NKI-AVL, Amsterdam, the Netherlands

Marie José Kersten

Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands;Lymphoma and Myeloma Center Amsterdam (LYMMCARE), the Netherlands